PGR2023-00043 - Intas Pharmaceuticals et al. v. Atossa Therapeutics IncReport Error
Details
PATENT NUMBER
APPL. NUMBER
17580428
PETITIONER
STATUS
Final Written Decision
FILING DATE
2023-08-18
INSTITUTION DATE
2024-01-31
TERMINATION DATE
2025-01-29
AUTHOR JUDGE
Timeline
Petition
Notice of Filing Date
Preliminary Response
Institution Decision
Final Decision
Aug
Sep
Oct
Nov
Dec
2024
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2025
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
Docket
1 | 2023-08-18 | Petitioner | Petition | Petition : as filed |
2 | 2023-08-18 | Petitioner | Power of Attorney | Notice : Power of Attorney |
1001 | 2023-08-18 | Petitioner | USPN 11,572,334 | |
1002 | 2023-08-18 | Petitioner | File history of USPN 11,572,334 | |
1003 | 2023-08-18 | Petitioner | USPN 9,333,190 (Ahmad) | |
1004 | 2023-08-18 | Petitioner | WO2017/70651 (Liu) | |
1005 | 2023-08-18 | Petitioner | WO 2012/050263 (Song) | |
1006 | 2023-08-18 | Petitioner | Ahmad, Endoxifen, a New Cornerstone of Breast Cancer (Ahmad 2010) | |
1007 | 2023-08-18 | Petitioner | Ahmad, Endoxifen for breast cancer (Ahmad 2012) | |
1008 | 2023-08-18 | Petitioner | Cole, Enteric coated HPMC (2002) (Cole) | |
1009 | 2023-08-18 | Petitioner | Ku, Performance qualification (2010) (Ku) | |
1010 | 2023-08-18 | Petitioner | Benameur, Capsule Technology (Benameur) | |
1011 | 2023-08-18 | Petitioner | Stegemann, Hard gelatin capsules (2002) (Stegemann) | |
1012 | 2023-08-18 | Petitioner | Excerpts of Handbook of Pharmaceutical Excipients | |
1013 | 2023-08-18 | Petitioner | Office Action dated 2/25/2020 from 16/641,985 | |
1014 | 2023-08-18 | Petitioner | Prescribing Information for Zonalta | |
1015 | 2023-08-18 | Petitioner | USP 711 | |
1016 | 2023-08-18 | Petitioner | Beasley (2015) | |
1017 | 2023-08-18 | Petitioner | Evans (1988) | |
1018 | 2023-08-18 | Petitioner | Ahmad, Endoxifen (Ahmad 2016) | |
1019 | 2023-08-18 | Petitioner | Milroy (2018) | |
1020 | 2023-08-18 | Petitioner | Expert Declaration of Jason McConville, Ph.D. | |
3 | 2023-08-30 | Board | Notice of Filing Date | Notice: Notice filing date accorded |
5 | 2023-09-08 | Potential Patent Owner | Mandatory Notice | Notice : Mandatory Notice |
6 | 2023-09-08 | Potential Patent Owner | Power of Attorney | Notice : Power of Attorney |
7 | 2023-11-30 | Potential Patent Owner | Preliminary Response | Patent Owner's Preliminary Response |
8 | 2023-11-30 | Potential Patent Owner | Other | Motion for Pro Hac Vice Admission (Susan M. Krumplitsch) |
2001 | 2023-11-30 | Potential Patent Owner | Expert Declaration of Stephen Graham Davies, D. Phil. (“Davies Decl.”) | |
2002 | 2023-11-30 | Potential Patent Owner | Elkins et al., Characterization of the isomeric configuration | |
2003 | 2023-11-30 | Potential Patent Owner | U.S. Patent No. 11,261,151 (“’151 patent”) | |
2004 | 2023-11-30 | Potential Patent Owner | Excerpt of ’151 Patent File History - IDS Filings, Receipts, List Considered | |
2005 | 2023-11-30 | Potential Patent Owner | Excerpt of ’151 Patent File History - Liu (“’985 File History 2”) | |
2006 | 2023-11-30 | Potential Patent Owner | Excerpt of ’151 Patent File History - FOA and NOA (“’985 File History 3”) | |
2007 | 2023-11-30 | Potential Patent Owner | Intl. Pub. No. WO 2010/135703A2 by Ahmad et al. | |
2008 | 2023-11-30 | Potential Patent Owner | Intl. Pub. No. WO 2009/032699A1 by Bortz et al. | |
2009 | 2023-11-30 | Potential Patent Owner | Intl. Pub. No. WO 2009/120999A2 by Kushner et al. | |
2010 | 2023-11-30 | Potential Patent Owner | Excerpt of File History for U.S. Patent 9,333,190 - Office Actions, Responses, Declarations, and Allowance | |
2011 | 2023-11-30 | Potential Patent Owner | Ali et al., “Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent | |
2012 | 2023-11-30 | Potential Patent Owner | International Counsel for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use | |
2013 | 2023-11-30 | Potential Patent Owner | Stephen Graham Davies, D. Phil. Curriculum Vitae | |
2014 | 2023-11-30 | Potential Patent Owner | Center for Drug Evaluation and Research, FDA Guidance Document, “Development of New Stereoisomeric Drugs,” | |
2015 | 2023-11-30 | Potential Patent Owner | Lv et al., “Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities,” | |
2016 | 2023-11-30 | Potential Patent Owner | Buchanan et al., “Solubilization and Dissolution of Tamoxifen-Hydroxybutenyl Cyclodextrin Complexes,” J. Pharm. Sciences, 95(10):2246-2255 (2006) (“Buchanan”) | |
2017 | 2023-11-30 | Potential Patent Owner | Gupta et al., “Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations,” Molecules, 23:1719 (2018) (“Gupta”) | |
2018 | 2023-11-30 | Potential Patent Owner | Jacques et al., Enantiomers, Racemates, and Resolutions (1981) (“Jacques”) | |
2019 | 2023-11-30 | Potential Patent Owner | Susan M. Krumplitsch Declaration in Support of Motion for Pro Hac Vice | |
9 | 2023-12-11 | Board | Other | Order: Granting Patent Owners Motion for Admission Pro Hac Vice of Susan M. Krumplitsch 37 C.F.R. sec. 42.10 |
10 | 2023-12-26 | Petitioner | Reply | Petitioner's Reply to Patent Owner's Preliminary Response |
11 | 2024-01-31 | Board | Institution Decision | Institution Decision: Grant |
12 | 2024-01-31 | Board | Other | SCHEDULING ORDER |
13 | 2024-03-12 | Patent Owner | Other | Patent Owner's Notice of Deposition of Jason McConville, Ph.D. |
14 | 2024-04-24 | Patent Owner | Response | Patent Owner Response to Petition |
2020 | 2024-04-24 | Patent Owner | Expert Declaration of Stephen Graham Davies, D. Phil. in Support of Patent Owner’s Response (“Davies POR Decl.”) | |
2021 | 2024-04-24 | Patent Owner | Deposition Transcript of Jason T. McConville, Ph.D. taken on April 12, 2024, in Intas Pharmaceuticals Ltd. v. Atossa Therapeutics, Inc., PGR2023-00043 (“McConville Tr.”) | |
2022 | 2024-04-24 | Patent Owner | Excerpt of File History for U.S. Patent 9,333,190 – Original Filed Application, Office Actions, Responses, Appeal of Examiner’s Decision, Declarations, and Allowance (“Ahmad File History Excerpt 2”) | |
2023 | 2024-04-24 | Patent Owner | Prescribing Information for Nolvadex (tamoxifen citrate tablets) | |
2024 | 2024-04-24 | Patent Owner | Prescribing Information for Soltamox (tamoxifen citrate solution) | |
2025 | 2024-04-24 | Patent Owner | Prescribing Information for Evista (raloxifene hydrochloride tablets) | |
2026 | 2024-04-24 | Patent Owner | Prescribing Information for Fareston (toremifene citrate tablets) | |
15 | 2024-06-10 | Petitioner | Other | Petitioner's Notice of Deposition of Stephen Graham Davies, D. Phil. |
16 | 2024-07-17 | Petitioner | Reply | Petitioner's Reply |
1022 | 2024-07-17 | Petitioner | Fauq (2010) | |
1023 | 2024-07-17 | Petitioner | Fauq (2010) Supplementary Material | |
1024 | 2024-07-17 | Petitioner | NMR Spectra | |
1025 | 2024-07-17 | Petitioner | Milroy Supplementary Material | |
1026 | 2024-07-17 | Petitioner | Majee (2017) | |
1027 | 2024-07-17 | Petitioner | Marzorati (2015) | |
1028 | 2024-07-17 | Petitioner | Al-Tabakha (2010) | |
1029 | 2024-07-17 | Petitioner | Honkanen (March 2004) | |
1030 | 2024-07-17 | Petitioner | Expert Declaration of Ron Bihovsky, Ph.D. | |
1031 | 2024-07-17 | Petitioner | Reply Expert Declaration of Jason McConville, Ph.D. | |
1032 | 2024-07-17 | Petitioner | HPE Excerpts | |
17 | 2024-07-29 | Patent Owner | Other | Patent Owner's Notice of Deposition of Dr. Jason McConville |
18 | 2024-07-29 | Patent Owner | Other | Patent Owner's Notice of Deposition of Dr. Ron Bihovsky |
19 | 2024-08-05 | Petitioner | Mandatory Notice | Petitioner's Updated Mandatory Notice Information |
20 | 2024-08-27 | Patent Owner | Other | Joint Stipulation to Modify Due Date 3 |
3001 | 2024-09-04 | Board | Exhibit 3001 | |
21 | 2024-09-06 | Patent Owner | Sur-Reply | Patent Owner's Sur-Reply to Petition for Post-Grant Review |
2027 | 2024-09-06 | Patent Owner | Deposition Transcript of Ron Bihovsky, Pd.D. taken on August 14, 2024 | |
2028 | 2024-09-06 | Patent Owner | Deposition Transcript of Jason T. McConville, Ph.D. taken on August 15, 2024 | |
2029 | 2024-09-06 | Patent Owner | Supplemental Declaration of Stephen Graham Davies, D. Phil. in Support of Patent Owner’s Sur-Reply | |
22 | 2024-09-13 | Petitioner | Other | Petitioner's Amended Notice of Deposition of Stephen Graham Davies, D. Phil. |
23 | 2024-09-18 | Patent Owner | Other | Patent Owner's Request for Oral Argument |
24 | 2024-09-18 | Petitioner | Other | Petitioner's Request for Oral Argument |
25 | 2024-09-25 | Board | Other | Order Setting Oral Argument |
26 | 2024-09-30 | Petitioner | Other | Petitioner's Observations on the Cross-Examination of Stephen G. Davies, D. Phil. |
1033 | 2024-09-30 | Petitioner | Dr. Davies Cross-Examination Transcript, 9/18/2024 | |
3002 | 2024-10-15 | Board | Ex. 3002 Request for authorization to file a Response | |
27 | 2024-10-21 | Patent Owner | Other | Patent Owner's Response to Petitioner's Observations on the Cross-Examination of Dr. Stephen G. Davies |
28 | 2024-10-22 | Board | Other | LEAP Practitioner Request and Verification Form (Petitioner) |
29 | 2024-10-29 | Petitioner | Other | Joint Identification of Objections to Oral Argument Demonstratives |
30 | 2024-10-30 | Patent Owner | Exhibit | Patent Owner's Updated Exhibit List |
31 | 2024-10-30 | Petitioner | Exhibit | Petitioner's Updated Exhibit List |
1034 | 2024-10-30 | Petitioner | Petitioner's Oral Argument Demonstratives | |
2030 | 2024-10-30 | Patent Owner | Patent Owner's Hearing Demonstratives | |
3003 | 2024-11-04 | Board | Ex. 3003 | |
32 | 2024-11-08 | Patent Owner | Power of Attorney | Patent Owner's Power of Attorney |
33 | 2024-11-08 | Patent Owner | Mandatory Notice | Patent Owner's Mandatory Notices Pursuant to 37 C.F.R. § 42.8 |
34 | 2024-11-21 | Board | Other | Other: Hearing transcript |
35 | 2025-01-08 | Patent Owner | Power of Attorney | Patent Owner's Updated Power of Attorney |
36 | 2025-01-08 | Patent Owner | Mandatory Notice | Patent Owner's Updated Mandatory Notices |
3004 | 2025-01-08 | Board | Ex. 3004 | |
37 | 2025-01-29 | Board | Final Decision | Determining All Challenged Claims Unpatentable 35 U.S.C. § 328(a) |
Grounds Asserted